SMC021A - absorption, efficacy and tolerance in patients with osteoarthritis. A placebo-controlled 14-days study

Trial Profile

SMC021A - absorption, efficacy and tolerance in patients with osteoarthritis. A placebo-controlled 14-days study

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2012

At a glance

  • Drugs Calcitonin (Primary)
  • Indications Osteoarthritis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Nordic Bioscience
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2010 Results published in Osteoarthritis and Cartilage.
    • 16 Oct 2009 Results were reported in an Emisphere Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top